נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development
Year:
2010
Source of publication :
Pancreas
Authors :
Genina, Olga
;
.
Honig, Hen
;
.
Pines, Mark
;
.
Spector, Itai
;
.
Volume :
39
Co-Authors:
Spector, I., Institute of Animal Sciences, ARO, Volcani Center, Bet Dagan 50250, Israel, Department of Animal Science, Faculty of Agriculture, Hebrew University of Jerusalem, Israel
Honig, H., Institute of Animal Sciences, ARO, Volcani Center, Bet Dagan 50250, Israel
Kawada, N., Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
Nagler, A., Department of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
Genin, O., Institute of Animal Sciences, ARO, Volcani Center, Bet Dagan 50250, Israel
Pines, M., Institute of Animal Sciences, ARO, Volcani Center, Bet Dagan 50250, Israel
Facilitators :
From page:
1008
To page:
1015
(
Total pages:
8
)
Abstract:
Objectives: Most solid tumors consist of neoplastic and nonneoplastic cells and extracellular matrix components. In the pancreas, activated stellate cells (PSCs) are the source of the extracellular matrix proteins. We evaluated the significance of PSC activation in tumor establishment and development in mouse xenografts. Methods: Xenografts were established by implanting human pancreatic cancer cells (MiaPaca-2) subcutaneously or orthotopically by injecting them into the spleen. Fibrosis was induced by cerulein. Collagen level was evaluated by Sirius red staining. Prolyl 4-hydroxylase β and stellate cell activation-associated protein (Cygb/STAP) were determined by immunohistochemistry. Results: Halofuginone inhibited subcutaneous tumor development implanted with Matrigel and reduced collagen and prolyl 4-hydroxylase β levels. Few tumors, which developed slowly, were observed after MiaPaca-2 implantation without Matrigel. Increase in tumor number and rate of development were observed with addition of PSCs from control pancreas, and further increase was observed when the PSCs were from cerulein-treated mice. Preincubation of the PSCs with halofuginone elicited Cygb/STAP level reduction and tumor growth inhibition. More tumors developed orthotopically in cerulein-treated mice than in controls; this was prevented by halofuginone. Conclusions: Extracellular matrix production by activated PSCs is essential for tumor establishment and growth. Thus, inhibition of PSC activation is a viable means of reducing pancreatic tumor development. Copyright © 2010 by Lippincott Williams & Wilkins.
Note:
Related Files :
animal cell
Animals
Carcinogenesis
drug effect
Male
mice
Pancreas
pancreas cell
Pancreatic Stellate Cells
Show More
Related Content
More details
DOI :
10.1097/MPA.0b013e3181da8aa3
Article number:
0
Affiliations:
Database:
Scopus
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
29386
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 00:46
Scientific Publication
Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development
39
Spector, I., Institute of Animal Sciences, ARO, Volcani Center, Bet Dagan 50250, Israel, Department of Animal Science, Faculty of Agriculture, Hebrew University of Jerusalem, Israel
Honig, H., Institute of Animal Sciences, ARO, Volcani Center, Bet Dagan 50250, Israel
Kawada, N., Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
Nagler, A., Department of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
Genin, O., Institute of Animal Sciences, ARO, Volcani Center, Bet Dagan 50250, Israel
Pines, M., Institute of Animal Sciences, ARO, Volcani Center, Bet Dagan 50250, Israel
Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development
Objectives: Most solid tumors consist of neoplastic and nonneoplastic cells and extracellular matrix components. In the pancreas, activated stellate cells (PSCs) are the source of the extracellular matrix proteins. We evaluated the significance of PSC activation in tumor establishment and development in mouse xenografts. Methods: Xenografts were established by implanting human pancreatic cancer cells (MiaPaca-2) subcutaneously or orthotopically by injecting them into the spleen. Fibrosis was induced by cerulein. Collagen level was evaluated by Sirius red staining. Prolyl 4-hydroxylase β and stellate cell activation-associated protein (Cygb/STAP) were determined by immunohistochemistry. Results: Halofuginone inhibited subcutaneous tumor development implanted with Matrigel and reduced collagen and prolyl 4-hydroxylase β levels. Few tumors, which developed slowly, were observed after MiaPaca-2 implantation without Matrigel. Increase in tumor number and rate of development were observed with addition of PSCs from control pancreas, and further increase was observed when the PSCs were from cerulein-treated mice. Preincubation of the PSCs with halofuginone elicited Cygb/STAP level reduction and tumor growth inhibition. More tumors developed orthotopically in cerulein-treated mice than in controls; this was prevented by halofuginone. Conclusions: Extracellular matrix production by activated PSCs is essential for tumor establishment and growth. Thus, inhibition of PSC activation is a viable means of reducing pancreatic tumor development. Copyright © 2010 by Lippincott Williams & Wilkins.
Scientific Publication
You may also be interested in